TITLE

Metformin Improved Glycemic Control in Patients with Type 1 Diabetes

AUTHOR(S)
Gottlieb, Peter A.; Ellis, Samuel L.; Lopez, Phillip; Gutin, Raymond; Garg, Satish K.
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA574
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this study was to evaluate glycemic control in adult patients with type 1 diabetes prescribed to metformin therapy from January 2000 to December 2005. Secondary outcomes included weight, BMI, and insulin dose. This was a retrospective study with a computer matched control group in patients with type 1 diabetes A total of 59 patients were included in this analysis. The control group was matched for age, gender, AIC and weight. The number of subjects on metformin included in the pre-post data analysis was 48, 40, 37 and 38 at 3, 6, 9 and 12 months, respectively. A separate analysis was conducted using a matched control group of 41 patients. Baseline characteristics included 40 (68%) women; mean age of 31.5 ± 10.4 years, A1C of 8.19 ± .1.42% and a BMI of 31.7 ± 5 kg/m² in the metformin group. Pre-post analysis of the 59 patients on metformin was performed at 3, 6, 9 and 12 months. A significant reduction in A1c was observed at 3 months (8.08 vs. 7.64%; p<0.001). A non-significant mean reduction in A1C of 0.35, 0.27 and 0.28 percent was observed at 6, 9 and 12 months, respectively. A significant reduction in weight was observed at 6 (200.2 vs. 197.5 pounds; p=0.01), 9 (202.2 vs. 198.5 pounds; p=0.008) and 12 months (204.4 vs. 200.1 pounds; p=0.003). Insulin requirements (units/kg) were significantly reduced at 3 and 6 months (p<0.02). In comparison to the control group a significant reduction in mean A1c was also observed at 3 months with metformin (0.53%; p=0.017). In conclusion overweight patients with type 1 diabetes initiated on metformin therapy had significant reductions in A1C, weight and insulin dose.
ACCESSION #
25822540

 

Related Articles

  • Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 Diabetes. Elkind-Hirsch, Karen; Butler, William J.; Bhushan, Madhu; Hirsch, David; Bhushan, Rajat // Diabetes Care;Jan2008, Vol. 31 Issue 1, p39 

    The article focuses on a study that involved adding pramlintide in patients with insulin-requiring type 2 diabetes. According to it, pramlintide added to insulin treatment in patients with type 2 diabetes was shown to reduce postprandial glucose levels, improve glycemic control, and promote...

  • Exenatide Use in Multiple Drug Regimens: Adjusting the Insulin and TZD. Oyer, David S.; Bettenhausen, Susan K.; Gallagher, Patrick // Diabetes;Jun2007 Supplement 1, Vol. 56, pA155 

    Exenatide is now an established treatment option in type 2 diabetes, but optimal use in multiple drug regimens is still being investigated. We report our experience in 160 patients (pts) started on exenatide. The average age was 62.9 yrs, 41% were female, and the average weight was 228 lbs....

  • Predictors of Achieving Glycemic Targets in Patients with Type 2 Diabetes Treated with Exenatide or Insulin: A Meta-Analysis. Brodows, Robert; Milton, Denái; Jie Mao; Wintle, Matthew; Trautmann, Michael // Diabetes;Jun2007 Supplement 1, Vol. 56, pA552 

    In two comparator trials (10µg exenatide BID vs. either insulin glargine or mixed insulin), both exenatide and insulin treatment achieved similar reductions in A1C for approximately 6 months, while exenatide was associated with weight loss and insulin associated with weight gain. Data were...

  • METFORMIN FOR WEIGHT LOSS.  // Life Extension;Sep2004, Vol. 10 Issue 9, p32 

    Points out that while metformin is used to treat diabetes, published research shows that it also helps non-diabetics to lose weight. Ability of metformin to reduce sugar release from liver to prevent blood glucose levels from rising too high, so that the body does not need to produce as much...

  • Me and My Byetta. Mendosa, David // Diabetes Health;Aug2006, Vol. 15 Issue 8, p41 

    The article relates the author's experience with Byetta, a drug developed to aid patients suffering from type 2 diabetes who are not able to control their blood sugar. An interview with an endocrinologist has made the author decide to use Byetta. The doctor told him Byetta is also proven to be...

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Improvements in Cardiovascular Risk Factors Accompanied Improved Glycemic Control and Weight Reduction in Patients With Type 2 Diabetes Treated With Exenatide for 3.5y. Kendall, David; Blonde, Lawrence; Mac, Susanna; Xuesong Guan; Holcombe, John; Okerson, Ted; Kim, Dennis; Bhole, Deepak // Diabetes;Jun2007 Supplement 1, Vol. 56, pA149 

    The article focuses on a study on the improvements in cardiovascular risk factors, glycemic control and weight reduction in type 2 diabetes patients treated with exenatide in 3.5 years conducted in the U.S. It cites that treatment with exenatide in type 2 diabetics has been associated with...

  • Twice-daily insulin regimens in management of severe diabetes. Oakley, Nigel; Mather, Hugh; Hadley, Lindsay; Lynch, Janice; Pilkington, Thomas // Journal of the Royal Society of Medicine;May1981, Vol. 74 Issue 5, p363 

    Diurnal glucose profiles have been compared in ten insulin dependent diabetics receiving, firstly, a twice-daily soluble insulin (SI): isophane insulin (NPHI) regimen containing a high proportion of SI (mean 73%O) and, secondly, Mixtard insulin (30% SI, 70% NPHI). For each patient the two...

  • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard; Rønn, Birgitte Biilmann // Diabetes;Jun2004, Vol. 53 Issue 6, p1614 

    The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics